Adults with moderate to severe atopic dermatitis are a step closer to being able to routinely access treatment with Sanofi’s Dupixent on the NHS, following a green light from cost regulators.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.